Rank |
Clinical Trial |
PubWeight™‹?› |
201
|
CATIE- Schizophrenia Trial
|
41.67
|
202
|
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)
|
41.54
|
203
|
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
|
41.47
|
204
|
Diabetes Prevention Program Outcomes Study (DPPOS)
|
41.46
|
205
|
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)
|
41.45
|
206
|
Family Heart Study (FHS)
|
41.40
|
207
|
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
|
41.38
|
208
|
Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)
|
41.16
|
209
|
PROMISE EBF: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV in Sub-Saharan Africa
|
41.10
|
210
|
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
|
41.00
|
211
|
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
|
40.91
|
212
|
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
|
40.67
|
213
|
Incidence of Diabetes and Cardiovascular Disease in Mexican Americans
|
40.56
|
214
|
Enhancing Recovery in Coronary Heart Disease (ENRICHD) Patients
|
40.52
|
215
|
|
40.35
|
216
|
Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)
|
40.31
|
217
|
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
|
40.30
|
218
|
Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes
|
40.22
|
219
|
A Phase 1/2 Study to Evaluate MEDI4736
|
40.18
|
220
|
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
|
40.14
|
221
|
Prevalence of Asymptomatic Ventricular Dysfunction
|
40.10
|
222
|
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)
|
40.09
|
223
|
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
|
40.07
|
224
|
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR
|
39.98
|
225
|
Multi-Ethnic Study of Atherosclerosis (MESA)
|
39.79
|
226
|
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
|
39.77
|
227
|
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
|
39.63
|
228
|
Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
|
39.45
|
229
|
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
|
39.31
|
230
|
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)
|
39.18
|
231
|
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
|
39.10
|
232
|
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
|
38.88
|
233
|
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)
|
38.86
|
234
|
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
|
38.83
|
235
|
Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis
|
38.78
|
236
|
Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO3/4)
|
38.67
|
237
|
The LIFE Study - Lifestyle Interventions and Independence for Elders (LIFE)
|
38.67
|
238
|
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
|
38.65
|
239
|
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
|
38.64
|
240
|
Family Blood Pressure Program - GENOA
|
38.52
|
241
|
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) (PIVENS)
|
38.44
|
242
|
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
|
38.41
|
243
|
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE)
|
38.39
|
244
|
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
|
38.24
|
245
|
Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates (ZVITAMBO)
|
38.20
|
246
|
CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)
|
38.20
|
247
|
Coronary Disease Morbidity and Mortality in a Population
|
38.11
|
248
|
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
|
38.00
|
249
|
Lung Health Study (LHS) I and III
|
37.98
|
250
|
Vitamin D and Omega-3 Trial (VITAL) (VITAL)
|
37.94
|
251
|
Preventing Obesity Using Novel Dietary Strategies
|
37.73
|
252
|
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (ALTTO)
|
37.72
|
253
|
Physicians' Health Study II (PHS II)
|
37.63
|
254
|
Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.
|
37.46
|
255
|
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
|
37.32
|
256
|
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
|
37.24
|
257
|
Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
|
37.14
|
258
|
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) (RELAX)
|
37.00
|
259
|
Genetics of Atherosclerosis in Mexican Americans
|
36.96
|
260
|
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) (TODAY)
|
36.89
|
261
|
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
|
36.89
|
262
|
Effects of Bariatric Surgery in Swedish Obese Subjects (SOS)
|
36.82
|
263
|
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (READY)
|
36.82
|
264
|
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT)
|
36.54
|
265
|
Neurocognitive Function in Snoring Children
|
36.42
|
266
|
Girls Health Enrichment Multi-Site Studies (GEMS)
|
36.35
|
267
|
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
|
36.34
|
268
|
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
|
36.26
|
269
|
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
|
36.20
|
270
|
Spine Patient Outcomes Research Trial (SPORT) - Intervertebral Disc Herniation (SPORT)
|
36.17
|
271
|
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)
|
36.08
|
272
|
Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS)
|
36.05
|
273
|
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-52)
|
35.97
|
274
|
Fluids and Catheters Treatment Trial (FACTT) - ARDS Clinical Research Network
|
35.95
|
275
|
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2)
|
35.94
|
276
|
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
|
35.85
|
277
|
Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago
|
35.80
|
278
|
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)
|
35.77
|
279
|
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
|
35.67
|
280
|
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)
|
35.58
|
281
|
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)
|
35.44
|
282
|
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
|
35.31
|
283
|
A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies (MK-8628-001)
|
35.27
|
284
|
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
|
35.26
|
285
|
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
|
35.20
|
286
|
Viral Therapy in Treating Patient With Liver Cancer
|
35.19
|
287
|
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)
|
35.16
|
288
|
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
|
35.08
|
289
|
Obesity Intervention "Obeldicks" for Obese Children, Adolescents and Their Parents (Obeldicks)
|
35.00
|
290
|
Clarification of Optimal Anticoagulation Through Genetics (COAG)
|
34.94
|
291
|
EVA3S: Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis
|
34.91
|
292
|
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
|
34.86
|
293
|
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
|
34.76
|
294
|
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
|
34.56
|
295
|
Protocolized Care for Early Septic Shock (ProCESS)
|
34.50
|
296
|
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)
|
34.46
|
297
|
Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial (ARISE)
|
34.41
|
298
|
Patient-Physician Partnership to Improve High Blood Pressure Adherence
|
34.41
|
299
|
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)
|
34.37
|
300
|
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)
|
34.37
|